You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
ITRACAP is indicated for use in adults for the treatment of:
Superficial dermatomycoses not responding to topical treatment.
Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
Pityriasis versicolor not responding to any other treatment.
Vulvovaginal candidiasis not responding to topical treatment.
Oral candidiasis in immunocompromised patients.
Onychomycosis caused by dermatophytes.
Systemic mycoses:
- Systemic aspergillosis, histoplasmosis, sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
ITRACAP is indicated for use in adults for the treatment of:
Superficial dermatomycoses not responding to topical treatment.
Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
Pityriasis versicolor not responding to any other treatment.
Vulvovaginal candidiasis not responding to topical treatment.
Oral candidiasis in immunocompromised patients.
Onychomycosis caused by dermatophytes.
Systemic mycoses:
- Systemic aspergillosis, histoplasmosis, sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
ITRACAP is indicated for use in adults for the treatment of:
Superficial dermatomycoses not responding to topical treatment.
Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
Pityriasis versicolor not responding to any other treatment.
Vulvovaginal candidiasis not responding to topical treatment.
Oral candidiasis in immunocompromised patients.
Onychomycosis caused by dermatophytes.
Systemic mycoses:
- Systemic aspergillosis, histoplasmosis, sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
ITRACAP is indicated for use in adults for the treatment of:
Superficial dermatomycoses not responding to topical treatment.
Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
Pityriasis versicolor not responding to any other treatment.
Vulvovaginal candidiasis not responding to topical treatment.
Oral candidiasis in immunocompromised patients.
Onychomycosis caused by dermatophytes.
Systemic mycoses:
- Systemic aspergillosis, histoplasmosis, sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
ITRACAP is indicated for use in adults for the treatment of:
Superficial dermatomycoses not responding to topical treatment.
Fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening.
Pityriasis versicolor not responding to any other treatment.
Vulvovaginal candidiasis not responding to topical treatment.
Oral candidiasis in immunocompromised patients.
Onychomycosis caused by dermatophytes.
Systemic mycoses:
- Systemic aspergillosis, histoplasmosis, sporotrichosis.
- Treatment and maintenance therapy in AIDS patients with disseminated or chronic pulmonary histoplasmosis infection.
- Treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective.
- Treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. This may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
